vs
Amphastar Pharmaceuticals, Inc.（AMPH）とEcovyst Inc.（ECVT）の財務データ比較。上の社名をクリックして会社を切り替えられます
Ecovyst Inc.の直近四半期売上が大きい（$199.4M vs $183.1M、Amphastar Pharmaceuticals, Inc.の約1.1倍）。Ecovyst Inc.の前年同期比売上増加率が高い（34.0% vs -1.8%）。Amphastar Pharmaceuticals, Inc.の直近四半期フリーキャッシュフローが多い（$24.6M vs $22.9M）。過去8四半期でEcovyst Inc.の売上複合成長率が高い（18.7% vs 3.2%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
Ecovyst Inc.は持続可能な特殊材料をグローバルに提供する企業で、高性能触媒と機能性添加剤の開発・製造を行っています。産業製造、消費財、環境保護などの分野の顧客に対し、業務効率化と炭素排出削減を支援するソリューションを提供しています。
AMPH vs ECVT — 直接比較
売上が大きい
ECVT
1.1倍大きい
$183.1M
売上成長率が高い
ECVT
+35.8%の差
-1.8%
フリーキャッシュフローが多い
AMPH
FCF $1.6M多い
$22.9M
2年売上CAGRが高い
ECVT
2年複合成長率
3.2%
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $199.4M |
| 純利益 | $24.4M | — |
| 粗利率 | 46.8% | 23.4% |
| 営業利益率 | 19.4% | 10.9% |
| 純利益率 | 13.3% | — |
| 売上前年比 | -1.8% | 34.0% |
| 純利益前年比 | -35.7% | — |
| EPS（希薄化後） | $0.51 | $0.06 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
売上AMPHECVT
| Q4 25 | $183.1M | $199.4M | ||
| Q3 25 | $191.8M | $204.9M | ||
| Q2 25 | $174.4M | $176.1M | ||
| Q1 25 | $170.5M | $143.1M | ||
| Q4 24 | $186.5M | $148.9M | ||
| Q3 24 | $191.2M | $153.9M | ||
| Q2 24 | $182.4M | $154.0M | ||
| Q1 24 | $171.8M | $141.6M |
純利益AMPHECVT
| Q4 25 | $24.4M | — | ||
| Q3 25 | $17.4M | $-79.3M | ||
| Q2 25 | $31.0M | $6.0M | ||
| Q1 25 | $25.3M | $-3.6M | ||
| Q4 24 | $38.0M | — | ||
| Q3 24 | $40.4M | $14.3M | ||
| Q2 24 | $37.9M | $8.3M | ||
| Q1 24 | $43.2M | $1.2M |
粗利率AMPHECVT
| Q4 25 | 46.8% | 23.4% | ||
| Q3 25 | 51.4% | 25.4% | ||
| Q2 25 | 49.6% | 22.8% | ||
| Q1 25 | 50.0% | 13.3% | ||
| Q4 24 | 46.5% | 28.9% | ||
| Q3 24 | 53.3% | 29.3% | ||
| Q2 24 | 52.2% | 27.3% | ||
| Q1 24 | 52.4% | 23.5% |
営業利益率AMPHECVT
| Q4 25 | 19.4% | 10.9% | ||
| Q3 25 | 13.2% | 13.8% | ||
| Q2 25 | 24.2% | 9.0% | ||
| Q1 25 | 21.9% | -0.7% | ||
| Q4 24 | 24.2% | 15.1% | ||
| Q3 24 | 29.8% | 17.9% | ||
| Q2 24 | 30.3% | 14.1% | ||
| Q1 24 | 27.9% | 9.5% |
純利益率AMPHECVT
| Q4 25 | 13.3% | — | ||
| Q3 25 | 9.0% | -38.7% | ||
| Q2 25 | 17.8% | 3.4% | ||
| Q1 25 | 14.8% | -2.5% | ||
| Q4 24 | 20.4% | — | ||
| Q3 24 | 21.1% | 9.3% | ||
| Q2 24 | 20.8% | 5.4% | ||
| Q1 24 | 25.1% | 0.9% |
EPS（希薄化後）AMPHECVT
| Q4 25 | $0.51 | $0.06 | ||
| Q3 25 | $0.37 | $-0.69 | ||
| Q2 25 | $0.64 | $0.05 | ||
| Q1 25 | $0.51 | $-0.03 | ||
| Q4 24 | $0.74 | $-0.26 | ||
| Q3 24 | $0.78 | $0.12 | ||
| Q2 24 | $0.73 | $0.07 | ||
| Q1 24 | $0.81 | $0.01 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $197.2M |
| 総負債低いほど良い | $608.7M | $392.6M |
| 株主資本純資産 | $788.8M | $603.4M |
| 総資産 | $1.6B | $1.3B |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | 0.65× |
8四半期トレンド — 暦四半期で整列
現金・短期投資AMPHECVT
| Q4 25 | $282.8M | $197.2M | ||
| Q3 25 | $276.2M | $82.0M | ||
| Q2 25 | $231.8M | $69.6M | ||
| Q1 25 | $236.9M | $127.5M | ||
| Q4 24 | $221.6M | $131.4M | ||
| Q3 24 | $250.5M | $123.5M | ||
| Q2 24 | $217.8M | $83.3M | ||
| Q1 24 | $289.6M | $103.1M |
総負債AMPHECVT
| Q4 25 | $608.7M | $392.6M | ||
| Q3 25 | $608.6M | $854.8M | ||
| Q2 25 | $607.7M | $856.6M | ||
| Q1 25 | $603.9M | $859.0M | ||
| Q4 24 | $601.6M | $860.8M | ||
| Q3 24 | $596.4M | $862.7M | ||
| Q2 24 | $586.9M | $862.4M | ||
| Q1 24 | $594.0M | $866.2M |
株主資本AMPHECVT
| Q4 25 | $788.8M | $603.4M | ||
| Q3 25 | $776.7M | $607.9M | ||
| Q2 25 | $757.5M | $692.4M | ||
| Q1 25 | $751.3M | $698.7M | ||
| Q4 24 | $732.3M | $700.5M | ||
| Q3 24 | $727.7M | $729.4M | ||
| Q2 24 | $713.3M | $717.3M | ||
| Q1 24 | $672.4M | $711.4M |
総資産AMPHECVT
| Q4 25 | $1.6B | $1.3B | ||
| Q3 25 | $1.7B | $1.7B | ||
| Q2 25 | $1.6B | $1.8B | ||
| Q1 25 | $1.6B | $1.8B | ||
| Q4 24 | $1.6B | $1.8B | ||
| Q3 24 | $1.5B | $1.8B | ||
| Q2 24 | $1.5B | $1.8B | ||
| Q1 24 | $1.6B | $1.8B |
負債/資本比率AMPHECVT
| Q4 25 | 0.77× | 0.65× | ||
| Q3 25 | 0.78× | 1.41× | ||
| Q2 25 | 0.80× | 1.24× | ||
| Q1 25 | 0.80× | 1.23× | ||
| Q4 24 | 0.82× | 1.23× | ||
| Q3 24 | 0.82× | 1.18× | ||
| Q2 24 | 0.82× | 1.20× | ||
| Q1 24 | 0.88× | 1.22× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $41.8M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | $22.9M |
| FCFマージンFCF / 売上 | 13.4% | 11.5% |
| 設備投資強度設備投資 / 売上 | 4.5% | 9.4% |
| キャッシュ転換率営業CF / 純利益 | 1.35× | — |
| 直近12ヶ月FCF直近4四半期 | $121.2M | $69.9M |
8四半期トレンド — 暦四半期で整列
営業キャッシュフローAMPHECVT
| Q4 25 | $32.9M | $41.8M | ||
| Q3 25 | $52.6M | $55.3M | ||
| Q2 25 | $35.6M | $33.0M | ||
| Q1 25 | $35.1M | $10.3M | ||
| Q4 24 | $29.0M | $43.5M | ||
| Q3 24 | $60.0M | $59.9M | ||
| Q2 24 | $69.1M | $10.0M | ||
| Q1 24 | $55.3M | $36.5M |
フリーキャッシュフローAMPHECVT
| Q4 25 | $24.6M | $22.9M | ||
| Q3 25 | $47.2M | $53.2M | ||
| Q2 25 | $25.0M | $7.8M | ||
| Q1 25 | $24.4M | $-14.0M | ||
| Q4 24 | $16.6M | $30.9M | ||
| Q3 24 | $46.2M | $53.6M | ||
| Q2 24 | $63.1M | $-9.3M | ||
| Q1 24 | $46.5M | $19.1M |
FCFマージンAMPHECVT
| Q4 25 | 13.4% | 11.5% | ||
| Q3 25 | 24.6% | 26.0% | ||
| Q2 25 | 14.3% | 4.4% | ||
| Q1 25 | 14.3% | -9.8% | ||
| Q4 24 | 8.9% | 20.7% | ||
| Q3 24 | 24.1% | 34.9% | ||
| Q2 24 | 34.6% | -6.1% | ||
| Q1 24 | 27.1% | 13.5% |
設備投資強度AMPHECVT
| Q4 25 | 4.5% | 9.4% | ||
| Q3 25 | 2.8% | 1.0% | ||
| Q2 25 | 6.1% | 14.4% | ||
| Q1 25 | 6.3% | 16.9% | ||
| Q4 24 | 6.7% | 8.5% | ||
| Q3 24 | 7.2% | 4.1% | ||
| Q2 24 | 3.3% | 12.5% | ||
| Q1 24 | 5.1% | 12.3% |
キャッシュ転換率AMPHECVT
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | 5.52× | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | 4.21× | ||
| Q2 24 | 1.82× | 1.20× | ||
| Q1 24 | 1.28× | 29.90× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
ECVT
| Industrial Mining Automotive | $101.3M | 51% |
| Regeneration And Treatment Services | $90.0M | 45% |
| Other | $8.1M | 4% |
